CR11383A - Derivados piridin-2-il-amino-1,2,4 -tiadiazol como activadores glucoquinasa para el tratamiento de la diabetes mellitus - Google Patents

Derivados piridin-2-il-amino-1,2,4 -tiadiazol como activadores glucoquinasa para el tratamiento de la diabetes mellitus

Info

Publication number
CR11383A
CR11383A CR11383A CR11383A CR11383A CR 11383 A CR11383 A CR 11383A CR 11383 A CR11383 A CR 11383A CR 11383 A CR11383 A CR 11383A CR 11383 A CR11383 A CR 11383A
Authority
CR
Costa Rica
Prior art keywords
treatment
glucoquinase
tiadiazol
piridin
activators
Prior art date
Application number
CR11383A
Other languages
English (en)
Inventor
Steven Armen Boyd
Mark Joseph Chicarelli
Kevin Ronald Condroski
Jay Bradford Fell
John P Fischer
Indrani W Gunawardana
Ajay Singh
Timothy M Turner
Eli M Wallace
Ronald Jay Hinklin
Thomas Daniel Aicher
Original Assignee
Array Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Array Biopharma Inc filed Critical Array Biopharma Inc
Publication of CR11383A publication Critical patent/CR11383A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se proporciona compuestos de la formula I en donde R2, R3, R13, L Y D2 son lo definido en la memoria descriptiva, que son utiles en el tratamiento y/o en la prevencion de enfermedades o trastornos mediados por niveles deficientes de actividad de glucocinasa o que se pueden tratar activando glucocinasa
CR11383A 2007-09-21 2010-04-21 Derivados piridin-2-il-amino-1,2,4 -tiadiazol como activadores glucoquinasa para el tratamiento de la diabetes mellitus CR11383A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US97422507P 2007-09-21 2007-09-21

Publications (1)

Publication Number Publication Date
CR11383A true CR11383A (es) 2010-08-13

Family

ID=40250949

Family Applications (2)

Application Number Title Priority Date Filing Date
CR11383A CR11383A (es) 2007-09-21 2010-04-21 Derivados piridin-2-il-amino-1,2,4 -tiadiazol como activadores glucoquinasa para el tratamiento de la diabetes mellitus
CR20150131A CR20150131A (es) 2007-09-21 2015-03-12 Derivados piridin-2-il-amino-1,2,4-tiadiazol como activadores glucoquinasa para el tratamiento de la diabetes mellitus

Family Applications After (1)

Application Number Title Priority Date Filing Date
CR20150131A CR20150131A (es) 2007-09-21 2015-03-12 Derivados piridin-2-il-amino-1,2,4-tiadiazol como activadores glucoquinasa para el tratamiento de la diabetes mellitus

Country Status (29)

Country Link
US (3) US8212045B2 (es)
EP (4) EP2727910B1 (es)
JP (1) JP5722037B2 (es)
KR (1) KR101566042B1 (es)
CN (1) CN101868459B (es)
AR (1) AR068628A1 (es)
AU (1) AU2008305294B2 (es)
BR (1) BRPI0816881A2 (es)
CA (1) CA2699718C (es)
CO (1) CO6270223A2 (es)
CR (2) CR11383A (es)
DK (1) DK2209778T3 (es)
EA (1) EA019104B1 (es)
ES (2) ES2393824T3 (es)
HK (2) HK1145498A1 (es)
HR (1) HRP20120814T1 (es)
IL (1) IL204264A (es)
MA (1) MA31779B1 (es)
MX (1) MX2010002772A (es)
MY (1) MY180558A (es)
NZ (1) NZ583538A (es)
PL (1) PL2209778T3 (es)
PT (1) PT2209778E (es)
SI (1) SI2209778T1 (es)
TN (1) TN2010000100A1 (es)
TW (1) TWI423799B (es)
UA (1) UA101166C2 (es)
WO (1) WO2009042435A1 (es)
ZA (2) ZA201002206B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2669687C (en) * 2006-11-15 2013-09-10 Forest Laboratories Holdings Limited Phthalazine derivatives
WO2009042435A1 (en) 2007-09-21 2009-04-02 Array Biopharma Inc. Pyridin-2 -yl-amino-i, 2, 4 -thiadiazole derivatives as glucokinase activators for the treatment of diabetes mellitus
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
CN102959076B (zh) 2010-03-31 2015-09-16 斯克里普斯研究所 重编程细胞
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
WO2012027261A1 (en) 2010-08-23 2012-03-01 Amgen Inc. Sulfonylpiperazine derivatives that interact with glucokinase regulatory protein for the treatment of diabetes
JPWO2012121314A1 (ja) 2011-03-09 2014-07-17 第一三共株式会社 ジピリジルアミン誘導体
EP2694491A1 (en) 2011-04-05 2014-02-12 Amgen Inc. Benzodioxepine and benzodioxine compounds that interact with glucokinase regulatory protein for the treatment of diabetes
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013123444A1 (en) 2012-02-17 2013-08-22 Amgen Inc. Sulfonyl compounds that interact with glucokinase regulatory protein
WO2013173382A1 (en) 2012-05-15 2013-11-21 Amgen Inc. Benzothiophene sulfonamides and other compounds that interact with glucokinase regulatory protein
WO2013173672A1 (en) * 2012-05-18 2013-11-21 Array Biopharma Inc. Method for the preparation of thiadiazoles
CA2890852A1 (en) * 2012-11-09 2014-05-15 Array Biopharma Inc. Crystalline forms of (1s)-1-[5-({3-[(2-methylpyridin-3-yl)oxy]-5-(pyridin-2-ylsulfanyl)pyridin-2-yl}amino)-1,2,4-thiadiazol-3-yl]ethane-1,2-diol
WO2016059647A2 (en) * 2014-10-13 2016-04-21 SHRI CHHATRAPTI SHIVAJI COLLEGE Maharashtra, India) Triaminotriazine picolinonitrile derivatives as potent reverse transcriptase inhibitor of hiv-1
GB201714777D0 (en) 2017-09-14 2017-11-01 Univ London Queen Mary Agent
BR112020008727A2 (pt) 2017-10-30 2020-10-20 Neuropore Therapies, Inc. fenil sulfonil fenil triazol tionas substituídas e usos destas
WO2019228362A1 (zh) 2018-05-31 2019-12-05 华领医药技术（上海）有限公司 含葡萄糖激酶激活剂和双胍类降糖药物的药物组合、组合物和复方制剂及其制备方法和用途

Family Cites Families (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3983246A (en) 1974-04-04 1976-09-28 Fmc Corporation N-(sulfonyloxy) benzimidoyl halides as bactericidal or fungicidal agents
DE2949913A1 (de) * 1979-12-12 1981-06-25 Basf Ag, 6700 Ludwigshafen Azofarbstoffe
EP0300688A1 (en) 1987-07-21 1989-01-25 FISONS plc Pyrrole derivatives, process for their preparation and pharmaceutical compositions containing them
JPH0228168A (ja) * 1988-04-14 1990-01-30 Sankyo Co Ltd チアゾール誘導体
US5326776A (en) 1992-03-02 1994-07-05 Abbott Laboratories Angiotensin II receptor antagonists
AU4090093A (en) 1992-05-29 1993-12-30 Yamanouchi Pharmaceutical Co., Ltd. Medicine containing benzoic acid derivative and novel benzoic acid derivative
WO1996000218A1 (en) 1994-06-24 1996-01-04 Euro-Celtique, S.A. Compounds for and method of inhibiting phosphodiesterase iv
GB9908410D0 (en) * 1999-04-13 1999-06-09 Pfizer Ltd Pyridines
ID30460A (id) 1999-04-15 2001-12-06 Bristol Myers Squibb Co Inhibitor-inhibitor protein siklik tirosin kinase
US7125875B2 (en) 1999-04-15 2006-10-24 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
HUP0201291A3 (en) 1999-04-28 2002-11-28 Sanofi Aventis Deutschland Di-aryl acid derivatives as ppar receptor ligands and pharmaceutical compositions containing them
IL146582A0 (en) 1999-05-21 2002-07-25 Biovitrum Ab Novel compounds, their use and preparation
US6465467B1 (en) 1999-05-21 2002-10-15 Biovitrum Ab Certain aryl-aliphatic and heteroaryl-aliphatic piperazinyl pyrazines and their use in the treatment of serotonin-related diseases
JP4144978B2 (ja) 1999-09-09 2008-09-03 富士フイルム株式会社 １，２，４−チアジアゾール誘導体の合成法
WO2001017995A1 (en) * 1999-09-10 2001-03-15 Merck & Co., Inc. Tyrosine kinase inhibitors
EP1242385B1 (en) 1999-12-28 2009-11-25 Pharmacopeia, Inc. Cytokine, especially tnf-alpha, inhibitors
US6906067B2 (en) 1999-12-28 2005-06-14 Bristol-Myers Squibb Company N-heterocyclic inhibitors of TNF-α expression
US20020065270A1 (en) 1999-12-28 2002-05-30 Moriarty Kevin Joseph N-heterocyclic inhibitors of TNF-alpha expression
US7345051B2 (en) 2000-01-31 2008-03-18 Genaera Corporation Mucin synthesis inhibitors
MXPA03001785A (es) 2000-08-31 2003-06-04 Pfizer Prod Inc Derivados de pirazol y su uso como inhibidores de proteina cinasa.
US20050209297A1 (en) 2000-08-31 2005-09-22 Pfizer Inc Pyrazole derivatives
AU2002213467A8 (en) 2000-10-11 2009-07-30 Chemocentryx Inc Modulation of ccr4 function
WO2002030357A2 (en) 2000-10-11 2002-04-18 Chemocentryx, Inc. Compounds and methods for modulating ccr4 function
AU3950802A (en) 2000-12-07 2002-06-18 Cv Therapeutics Inc Abca-1 elevating compounds
IL156369A0 (en) 2000-12-21 2004-01-04 Vertex Pharma Pyrazole derivatives and pharmaceutical compositions containing the same
AU2002258400A1 (en) 2001-02-16 2002-08-28 Tularik Inc. Methods of using pyrimidine-based antiviral agents
WO2002094264A1 (en) 2001-05-23 2002-11-28 Tularik Inc. Ccr4 antagonists
PE20030008A1 (es) 2001-06-19 2003-01-22 Bristol Myers Squibb Co Inhibidores duales de pde 7 y pde 4
HUP0402352A2 (hu) 2001-06-19 2005-02-28 Bristol-Myers Squibb Co. Foszfodiészteráz (PDE) 7 inhibitorként alkalmazható pirimidinszármazékok és ezeket tartalmazó gyógyszerkészítmények
JP2004535437A (ja) * 2001-06-22 2004-11-25 メルク　エンド　カムパニー　インコーポレーテッド チロシンキナーゼ阻害剤
AU2003202263A1 (en) 2002-01-10 2003-07-30 Bayer Healthcare Ag Roh-kinase inhibitors
CN1625410A (zh) 2002-02-05 2005-06-08 山之内制药株式会社 2,4,6－三氨基－1,3,5－三嗪衍生物
EP1485380B1 (en) 2002-03-15 2010-05-19 Vertex Pharmaceuticals Incorporated Azolylaminoazines as inhibitors of protein kinases
WO2003078426A1 (en) 2002-03-15 2003-09-25 Vertex Pharmaceuticals, Inc. Azolylaminoazine as inhibitors of protein kinases
US6846928B2 (en) 2002-03-15 2005-01-25 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of protein kinases
AU2003220299A1 (en) 2002-03-15 2003-09-29 Vertex Pharmaceuticals, Inc. Azinylaminoazoles as inhibitors of protein kinases
CA2480638C (en) 2002-03-29 2013-02-12 Chiron Corporation Substituted benzazoles and use thereof as raf kinase inhibitors
US8299108B2 (en) 2002-03-29 2012-10-30 Novartis Ag Substituted benzazoles and methods of their use as inhibitors of raf kinase
WO2003091213A1 (fr) * 2002-04-25 2003-11-06 Yamanouchi Pharmaceutical Co., Ltd. Derives d'amide ou sels de ces derives
AU2003249369A1 (en) 2002-06-21 2004-01-06 Cellular Genomics, Inc. Certain amino-substituted monocycles as kinase modulators
MXPA05001592A (es) 2002-08-09 2005-05-05 Astrazeneca Ab Oxadiazoles como moduladores de receptor-5 de glutamato metabotropico.
BR0314196A (pt) 2002-09-10 2005-07-26 Scios Inc Inibidores de tgf-beta
US7812167B2 (en) 2002-10-03 2010-10-12 Novartis, Ag Substituted (thiazol-2-yl)-amides or sulfonamides as glucokinase activators useful in the treatment of type 2 diabetes
AU2003285007A1 (en) 2002-10-30 2004-06-07 Merck & Co., Inc. Kinase inhibitors
JP4675318B2 (ja) 2003-02-10 2011-04-20 バーテックス ファーマシューティカルズ インコーポレイテッド Ｎ−アリールカルバミン酸エステルとハロ−ヘテロアリールとを反応させることによるｎ−ヘテロアリール−ｎ−アリール−アミンの調製のためのプロセスおよび類似のプロセス
US20040248850A1 (en) 2003-02-11 2004-12-09 Kemia, Inc. Compounds for the treatment of HIV infection
NZ540791A (en) 2003-02-13 2009-09-25 Banyu Pharma Co Ltd Novel 2-pyridinecarboxamide derivatives
WO2004087699A2 (en) 2003-03-25 2004-10-14 Vertex Pharmaceuticals Incorporated Thiazoles useful as inhibitors of protein kinases
US7244763B2 (en) 2003-04-17 2007-07-17 Warner Lambert Company Llc Compounds that modulate PPAR activity and methods of preparation
US20070027321A1 (en) 2003-09-02 2007-02-01 Kamenecka Theodore M Bipyridyl amines and ethers as modulators of metabotropic glutamate receptor-5
US7470712B2 (en) 2004-01-21 2008-12-30 Bristol-Myers Squibb Company Amino-benzazoles as P2Y1 receptor inhibitors
WO2005077373A2 (en) 2004-02-03 2005-08-25 Astrazeneca Ab Treatment of gastro-esophageal reflux disease (gerd)
AR049418A1 (es) 2004-02-27 2006-08-02 Bayer Pharmaceuticals Corp Derivados de heteroarilaminopirazol y composiciones farmaceuticas para el tratamiento de la diabetes.
KR20050091462A (ko) 2004-03-12 2005-09-15 한국과학기술연구원 푸로피리미딘 화합물 및 이를 포함하는 ｄｄｒ2 티로신키나아제 활성 저해제
EP1734040A4 (en) 2004-03-23 2007-11-28 Banyu Pharma Co Ltd SUBSTITUTED CHINAZOLINE OR PYRIDOPYRIMIDINE DERIVATIVE
EP1737870A1 (en) 2004-04-02 2007-01-03 Novartis AG Thiazolopyridine derivates, pharmaceutical conditions containing them and methods of treating glucokinase mediated conditions
EP1742935B1 (en) 2004-04-13 2010-02-24 Icagen, Inc. Polycyclic pyrazines as potassium ion channel modulators
AU2005233642A1 (en) 2004-04-13 2005-10-27 Astellas Pharma Inc. Polycyclic pyridines as potassium ion channel modulators
TW200606129A (en) * 2004-07-26 2006-02-16 Chugai Pharmaceutical Co Ltd Novel cyclohexane derivative, its prodrug, its salt and diabetic therapeutic agent containing the same
JP2008526734A (ja) 2004-12-31 2008-07-24 エスケー ケミカルズ カンパニー リミテッド 糖尿及び肥満治療予防に有効なキナゾリン誘導体
EP1954696B1 (en) 2005-01-19 2011-02-23 Bristol-Myers Squibb Company 2-phenoxy-n-(1,3,4-thiadizol-2-yl)pyridin-3-amine derivatives and related compounds as p2y1 receptor inhibitors for the treatment of thromboembolic disorders
DE102005025161A1 (de) 2005-06-01 2006-12-07 Phenion Gmbh & Co. Kg Derivate des Pyrimidins und Triazins und deren Verwendung
US7737151B2 (en) 2005-08-18 2010-06-15 Vertex Pharmaceuticals Incorporated Pyrazine kinase inhibitors
BRPI0615236A2 (pt) * 2005-08-31 2011-05-10 Astellas Pharma Inc derivado de tiazol
WO2007038387A2 (en) 2005-09-23 2007-04-05 Yale University Compounds and methods for the treatment of viruses and cancer
ES2372540T3 (es) * 2005-11-01 2012-01-23 Array Biopharma, Inc. Activadores de glucocinasa.
JP5328361B2 (ja) 2005-11-03 2013-10-30 バーテックス ファーマシューティカルズ インコーポレイテッド キナーゼインヒビターとして有用なアミノピリミジン
KR20070052207A (ko) 2005-11-16 2007-05-21 주식회사 엘지생명과학 신규한 ｋｄｒ 억제제
CN101360740A (zh) 2005-11-16 2009-02-04 沃泰克斯药物股份有限公司 可用作激酶抑制剂的氨基嘧啶
WO2007089512A1 (en) * 2006-01-27 2007-08-09 Array Biopharma Inc. Glucokinase activators
PT2013204E (pt) * 2006-03-24 2015-06-09 Array Biopharma Inc Análogos de 2-aminopiridina como activadores da glucoquinase
ES2352320T3 (es) 2006-05-12 2011-02-17 Ab Science Nuevo procedimiento para la síntesis de compuestos de 2-aminoxazol.
WO2008024963A1 (en) 2006-08-24 2008-02-28 Serenex, Inc. Benzene, pyridine, and pyridazine derivatives
TW200825060A (en) 2006-10-26 2008-06-16 Astrazeneca Ab Chemical compounds
MX2009006081A (es) 2006-12-08 2009-06-17 Irmc Llc Compuestos y composiciones como inhibidores de cinasa de proteina.
US8431713B2 (en) 2007-01-24 2013-04-30 Array Biopharma, Inc. 2-aminopyridine derivatives as glucokinase activators
CA2681695A1 (en) 2007-03-23 2008-10-02 Array Biopharma Inc. 2-aminopyridine analogs as glucokinase activators
US7776857B2 (en) 2007-04-05 2010-08-17 Amgen Inc. Aurora kinase modulators and method of use
US20090012091A1 (en) 2007-07-02 2009-01-08 Kinagen, Inc. Oximide derivatives and their therapeutical application
UY31281A1 (es) 2007-08-13 2009-03-31 Aminas, benzamidas y sulfonamidas {[4-(5,6-dimetil-2-piridin-2-il-piridin-3-il) oxipiridin-2-il]amino} sustituidas, sus sales farmacéuticamente aceptables, composiciones contenniéndolas y aplicaciones.
WO2009042435A1 (en) 2007-09-21 2009-04-02 Array Biopharma Inc. Pyridin-2 -yl-amino-i, 2, 4 -thiadiazole derivatives as glucokinase activators for the treatment of diabetes mellitus
SI2195312T1 (sl) 2007-10-09 2013-01-31 Merck Patent Gmbh Derivati piridina, uporabni kot aktivatorji glukokinaze

Also Published As

Publication number Publication date
JP5722037B2 (ja) 2015-05-20
US20150057448A1 (en) 2015-02-26
ES2569734T3 (es) 2016-05-12
MA31779B1 (fr) 2010-10-01
EP2209778A1 (en) 2010-07-28
TW200914007A (en) 2009-04-01
AU2008305294B2 (en) 2012-11-29
JP2010540443A (ja) 2010-12-24
US20120277242A1 (en) 2012-11-01
EP2209778B1 (en) 2012-08-29
ES2393824T3 (es) 2012-12-28
EP3078662A1 (en) 2016-10-12
US8212045B2 (en) 2012-07-03
WO2009042435A1 (en) 2009-04-02
US20100204240A1 (en) 2010-08-12
US8853409B2 (en) 2014-10-07
TN2010000100A1 (en) 2011-09-26
KR20100080809A (ko) 2010-07-12
AU2008305294A1 (en) 2009-04-02
CO6270223A2 (es) 2011-04-20
EP2573087A1 (en) 2013-03-27
MY180558A (en) 2020-12-02
WO2009042435A8 (en) 2009-10-08
ZA201002206B (en) 2011-06-29
PT2209778E (pt) 2012-12-06
MX2010002772A (es) 2010-03-31
US9079890B2 (en) 2015-07-14
KR101566042B1 (ko) 2015-11-04
SI2209778T1 (sl) 2012-12-31
HK1145498A1 (en) 2011-04-21
CN101868459A (zh) 2010-10-20
AR068628A1 (es) 2009-11-25
BRPI0816881A2 (pt) 2015-03-17
NZ583538A (en) 2012-06-29
HRP20120814T1 (hr) 2012-11-30
IL204264A (en) 2015-06-30
CR20150131A (es) 2015-04-30
DK2209778T3 (da) 2012-09-17
EA019104B1 (ru) 2014-01-30
UA101166C2 (ru) 2013-03-11
PL2209778T3 (pl) 2013-02-28
ZA201102350B (en) 2012-09-26
CA2699718C (en) 2014-05-27
HK1197821A1 (zh) 2015-02-18
TWI423799B (zh) 2014-01-21
EA201000515A1 (ru) 2010-10-29
EP2727910B1 (en) 2016-03-16
EP2727910A1 (en) 2014-05-07
CA2699718A1 (en) 2009-04-02
CN101868459B (zh) 2013-12-18

Similar Documents

Publication Publication Date Title
CR11383A (es) Derivados piridin-2-il-amino-1,2,4 -tiadiazol como activadores glucoquinasa para el tratamiento de la diabetes mellitus
ATE521608T1 (de) Glucokinaseaktivatoren
SG170775A1 (en) 2 -aminopyridine analogs as glucokinase activators
TW200740804A (en) Glucokinase activators
WO2008118718A3 (en) 2-aminopyridine analogs as glucokinase activators
DOP2011000279A (es) Derivados de benzofuranilo usados como inhibidores de glucoquinasa
GT200800184A (es) Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa-iv para el tratamiento o prevencion de diabetes.
BRPI0808775A2 (pt) compostos e composições como moduladores de atividade de gpr119
CO6491058A2 (es) Derivados de oxazina y su uso como inhibidores de bace para el tratamiento de trastornos neurológicos
ECSP088210A (es) Bencimidazoles sustituidos y métodos de preparación
PE20121617A1 (es) Derivados de oxazina como inhibidores de bace
CU20090148A7 (es) 4-aril-1,4-dihidro-1,6-naftiridinamidas sustituidas y su uso
UY32968A (es) Compuestos heterocíclicos fusionados como moduladores del receptor de orexina
TN2010000122A1 (en) Compounds and compositions as modulators of gpr119 activity
ECSP12012065A (es) Derivados de pirazina y su uso en el tratamiento de trastornos neurológicos
ECSP10010654A (es) Derivados de tienopiridonas como activadores de proteína quinasa activados por amp (ampk)
CR20110103A (es) Heteroarilos sustituidos
UA94639C2 (ru) Трициклические соединения и их применение как модуляторов глюкокортикоидного рецептора
TW200736233A (en) Cyclohexyl piperazinyl methanone derivatives
ATE541832T1 (de) Neuartige p2x7r-antagonisten und ihre verwendung
MX2009003645A (es) Azaciclilaminas n-sustituidas como antagonistas de histamina-3.
CR8928A (es) Derivados arilsulfonilestilbeno para tratamiento de insomnio y afecciones relacionadas
EP2438923A4 (en) COMPOSITION FOR THE PREVENTION OR TREATMENT OF OBESITY-RELATED DISORDERS MEDIATED BY AMPK ACTIVATION AND THE ACTIVE INGREDIENTS OF WHICH HAVE 2,5-BIS-ARYL-3,4-DIMETHYLTETRAHYDROFURAN LIGNANS
ECSP088922A (es) Derivados de amino-tiazol y sus usos como agentes antibacterianos
MX2010004309A (es) Moduladores de piperidinil y piperazinil de gamma-secretasa.